EU/3/18/2006 - orphan designation for treatment of malignant mesothelioma
tazemetostat
Orphan
Human
Overview
On 21 March 2018, orphan designation (EU/3/18/2006) was granted by the European Commission to Quintiles Ireland Limited, Ireland, for tazemetostat for the treatment of malignant mesothelioma.
In May 2018, Quintiles Ireland Limited changed name to IQVIA RDS Ireland Limited.
The sponsorship was transferred to Voisin Consulting S.A.R.L., France, in June 2019.
In October 2021, Voisin Consulting S.A.R.L. changed name to Voisin Consulting Life Sciences.
Malignant mesothelioma is a cancer that affects the mesothelial cells (found on the inner linings of the organs), mainly in the pleura (the lining of the lungs) and in the peritoneum (the lining of the abdominal cavity). It is usually caused by contact with asbestos. Mesothelioma of the pleura causes difficulty breathing and chest pain, and mesothelioma of the peritoneum causes ascites (a build-up of fluid in the abdomen) and abdominal pain.
Malignant mesothelioma is life-threatening because it may lead to heart or breathing problems, lung infections and bowel obstruction. Patients have very poor survival, only living for a year, on average, after diagnosis.
At the time of designation, malignant mesothelioma affected less than 1 in 10,000 people in the European Union (EU). This was equivalent to a total of fewer than 52,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 517,400,000 (Eurostat 2018).
At the time of designation, the main treatments for malignant mesothelioma were surgery and chemotherapy (medicines to treat cancer) with or without radiotherapy (treatment with radiation). If the disease was too advanced for surgery, chemotherapy alone was used. One medicine, pemetrexed, was authorised throughout the EU for the treatment of malignant pleural mesothelioma in combination with cisplatin. A second medicine, raltitrexed, was authorised for the treatment of malignant pleural mesothelioma in some European countries.
The sponsor has provided sufficient information to show that the medicine might be of significant benefit for patients with malignant mesothelioma because early results from studies indicate that tazemetostat might stop the disease getting worse in patients whose disease has not responded to authorised medicines or has come back afterwards. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
Tazemetostat blocks the action of a protein called EZH2. Some patients with malignant mesothelioma produce large amounts of the EZH2 protein, which encourages abnormal growth and development of mesothelial cells. By blocking EZH2, tazememostat is expected to lead to the death of the mesothelial cells and thus reduce the growth of the cancer.
The effects of tazemetostat have been evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials with tazemetostat in patients with malignant mesothelioma were ongoing.
At the time of submission, tazemetostat was not authorised anywhere in the EU for malignant mesothelioma. Orphan designation of the medicine had been granted in the United States for mesothelioma.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 15 February 2018 recommending the granting of this designation.
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
Key facts
- Active substance
- tazemetostat
- Intended use
- Treatment of malignant mesothelioma
- Orphan designation status
- Positive
- EU designation number
- EU/3/18/2006
- Date of designation
- Sponsor
Ipsen Pharma
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Update history
| Date | Update |
|---|---|
| April 2023 | The sponsorship was transferred from Voisin Consulting Life Sciences, France, to Ipsen Pharma, France. |
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: